pharmaceutical investing Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Disorder and Postpartum Depression based on FDA Breakthrough Therapy Meetin
Seegnal's operating subsidiary Seegnal E-Health Ltd. hires AI VP to Strengthen AI Capabilities and Accelerates Development of Seegnal Guard
